Northwire Canada EditionSunday, October 18, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0% GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0%
Other

Aurora Spine Launches New Biologics Portfolio

By The Northwire Desk — AI Analysis Oct 27, 2025 · 17:01 ASG · 0.315 Aurora Spine Corporation
ASG · Price

Executive Summary

  • Aurora Spine announced the creation of Aurora Biologics, a new division delivering allograft biologic products for spinal fusion.
  • The launch adds three flagship biologic offerings—TURBO FUSE™ Fiber Putty, OSTEO GRAFT™ DBM Putty, and OSTEO BRIDGE™ Sponge Strips—designed to work with Aurora’s existing minimally invasive implant portfolio.
  • Management projects the new biologics line will generate >30 % revenue growth over prior biologic offerings, enhancing margins and creating a “new profit engine” for the company.

Key Details

  • Division Formation: Aurora Biologics established as an integrated platform to combine mechanical fusion systems (ZIP™, Hydra A.E.R.O.™, DEXA™, SiLO™) with regenerative biologic solutions.
  • Product Suite:
  • TURBO FUSE™ Fiber Putty – dematerialized bone fibers for increased surface area and cellular attachment.
  • OSTEO GRAFT™ DBM Putty – demineralized cortical bone graft, moldable, carrier‑free.
  • OSTEO BRIDGE™ Sponge Strips – sponge‑like, conformable bone substitute for void filling and structural regeneration.
  • All products are 100 % allograft bone, free of synthetic carriers, providing osteoconductive and osteoinductive properties.
  • Strategic Rationale: Provides a seamless, fully integrated portfolio from implantation to healing phase, aiming to improve patient outcomes, surgical efficiency, and long‑term fusion integrity.
  • Financial Outlook (Management Commentary): Anticipated >30 % increase in revenue from biologics versus prior offerings; expected margin uplift and a new profit driver for Aurora Spine.
  • Executive Comments:
  • Mathew Goldstone, Chief Commercial Officer – emphasizes completion of an integrated portfolio covering both mechanical and biological aspects of fusion.
  • Trent J. Northcutt, President & CEO – highlights the biologics line as a strong growth catalyst and margin enhancer.

Notable Quotes

  • “Aurora Biologics completes our strategy of providing customers with a seamless, fully integrated portfolio.” – Mathew Goldstone, Chief Commercial Officer
  • “We anticipate more than a 30 percent increase over prior biologic offerings—driving stronger margins and creating a powerful new profit engine for Aurora Spine.” – Trent J. Northcutt, President & CEO
Read the original news release →

More from Aurora Spine Corporation

May 28, 2026 · 07:15

Aurora Spine Stabilizes Operations with First EBITDAC Profit, Yet Revenue Stagnation and Cash Burn Raise Liquidity Concerns

Earnings May 07, 2026 · 07:15

Patent Milestone Masks Cash Strain and Debt Overhang Despite EBITDAC Turnaround

Other Apr 30, 2026 · 07:15

Aurora Spine Posts Record Revenue as Turnaround Strategy Takes Hold

Earnings Mar 04, 2026 · 18:28

Aurora Spine cuts loan rate, extends insider note

Financings Mar 04, 2026 · 17:01

AURORA SPINE CORPORATION ANNOUNCES AMENDMENT TO LOAN FROM INSIDER

Financings Jan 08, 2026 · 16:28

Aurora Spine receives two U.S. patents

M&A / Property